Erlotinib (OSI-774, Tarceva™), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer

Mary Hightower, Chandra Belani, Vinay K. Jain

Research output: Contribution to journalArticle

13 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)336-338
Number of pages3
JournalClinical Lung Cancer
Volume4
Issue number6
DOIs
StatePublished - Jan 1 2003

Fingerprint

Combination Drug Therapy
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Erlotinib Hydrochloride

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

@article{c5b6e05f850b494ebc36d21ad5a27a81,
title = "Erlotinib (OSI-774, Tarceva™), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer",
author = "Mary Hightower and Chandra Belani and Jain, {Vinay K.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1525-7304(11)70302-3",
language = "English (US)",
volume = "4",
pages = "336--338",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Erlotinib (OSI-774, Tarceva™), a selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with chemotherapy for advanced non-small-cell lung cancer

AU - Hightower, Mary

AU - Belani, Chandra

AU - Jain, Vinay K.

PY - 2003/1/1

Y1 - 2003/1/1

UR - http://www.scopus.com/inward/record.url?scp=0038080166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038080166&partnerID=8YFLogxK

U2 - 10.1016/S1525-7304(11)70302-3

DO - 10.1016/S1525-7304(11)70302-3

M3 - Article

VL - 4

SP - 336

EP - 338

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -